An Eighteen Month Efficacy and Safety Study in Obese Patients (0364-020)(COMPLETED)

An 18-Month Study to Assess the Safety, Tolerability, and Efficacy of MK0364 in Obese Patients

Status

Completed

Phases

Phase 2Phase 3

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT00131430

Enrollment

500

Registered

2005-08-18

Start date

2005-08-31

Completion date

2007-05-31

Last updated

2016-06-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Obesity and Obesity-related Medical Conditions

Brief summary

A study to determine the safety and efficacy of an investigational drug in patients with obesity.

Interventions

DRUGtaranabant

Study design

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

TREATMENT

Masking

DOUBLE (Subject, Investigator)

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

* Obese patients with a body mass index between 30kg/m2 and 43 kg/m2, inclusive (BMI between 27 kg/m2 and 43kg/m2, inclusive for those with obesity-related comorbidities including hypertension, dyslipidemia and sleep apnea).

Exclusion criteria

* Patients with serious or unstable current or past medical conditions.

Design outcomes

Primary

Measure	Time frame
After 24 weeks, body weight, safety, and tolerability	After 24 weeks

Secondary

Measure	Time frame
After 80 weeks, body weight	After 80 weeks

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026